Mirvaso in Use Study

Phase 4

Completed

• Conditions: Rosacea
• Interventions: Drug: Brimonidine

• Registration Number: NCT02249065
• Lead Sponsor: Galderma R&D

Brief Summary

This study is designed to:

1. assess the signs and symptoms of rosacea, including erythema, without treatment and during treatment with Mirvaso® gel

2. further characterize lifestyle impact and patient satisfaction with Mirvaso® treatment

3. gain a better understanding of the real-world use of Mirvaso® on the pattern and management of facial erythema of rosacea.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-09
• Study First Submitted: 2014-09-23
• Study First Submitted QC: 2014-09-23
• Study First Posted: 2014-09-25
• Primary Completion: 2015-08
• Study Completion: 2015-08
• Results First Submitted: 2017-09-19
• Results First Submitted QC: 2017-09-19
• Results First Posted: 2017-10-19
• Status Verified: 2017-11
• Last Update Submitted: 2022-07-28
• Last Update Posted: 2022-08-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 205

Inclusion Criteria

1. Subjects must be 18 years of age or older at time of study consent.
2. Subjects with a board certified dermatologist (BCD) clinical diagnosis of facial erythema of rosacea and eligible for treatment with Mirvaso® (brimonidine) topical gel, 0.33% per package insert.
3. Subjects with a clinician's erythema assessment (CEA) score of ~3 at Screening Visit 1.
4. Subjects with less than 3 facial inflammatory lesions of rosacea at Screening/Visit 1.
5. Subjects must be willing and able to give written informed consent including photography consent. Consent and photo consent will be obtained prior to any study related procedures
6. Females of childbearing potential with a negative urine pregnancy test (UPT) at Visit 1 (prior to test article application) or females of non-childbearing potential (deemed as post-menopausal [absence of menstrual bleeding for at least 1 year prior to enrollment], hysterectomy or bilateral oophorectomy).

Exclusion Criteria

1. Subjects with particular forms of rosacea (rosacea conglobata, rosacea fulminans, isolated rhinophyma, isolated pustulosis of the chin) or other concomitant facial dermatoses that are similar to rosacea such as peri-oral dermatitis, demodicidosis, facial keratosis pilaris, seborrheic dermatitis, acute lupus erythematosus, or actinic telangiectasia.
2. Subjects with current diagnosis of Raynaud's syndrome, thromboangiitis obliterans, orthostatic hypotension, severe cardiovascular disease, cerebral or coronary insufficiency, renal or hepatic impairment, scleroderma, Sjogren's syndrome or depression.
3. Subjects with previous refractive eye surgery such as photorefractive keratectomy, laser-assisted sub-epithelial keratectomy, or laser-assisted in situ keratomileusis.
4. Current treatment with monoamine oxidase inhibitors.
5. Current treatment with barbiturates, opiates, sedatives, systemic anesthetics, or alpha- agonists.
6. Less than 3 months (90 days) stable dose treatment with tricyclic antidepressants, cardiac glycosides, beta blockers or other antihypertensive agents.
7. Subjects with any uncontrolled chronic or serious disease or medical condition that would normally prevent participation in a clinical study, or, in the judgment of the investigator, would put the subjects at undue risk, or might confound the study assessments (e.g., other dermatological diseases), or might interfere with the subjects' participation in the study, (e.g., planned hospitalization during the study).
8. Subjects who have received, applied, or taken treatments with drugs, cosmetics or devices known to cause facial erythema and who are deemed ineligible by the investigator.
9. Subjects with known allergies or sensitivities to any component of the study drug, including the active ingredient brimonidine tartrate label (refer to the package insert for Mirvaso® (brimonidine) topical gel, 0.33%).
10. Subjects with prior treatment with brimonidine gel, oxymetazoline or other (topical and/or systemic) alpha adrenergic agonists.
11. Subjects who are pregnant or breast-feeding or planning to become pregnant during the course of the study.
12. Subjects exposed to excessive ultraviolet (UV) radiation within I week prior to baseline and/or subject was unwilling to refrain from excessive exposure to UV radiation during the course of the study.
13. Subjects with the presence of a beard or excessive facial hair that would interfere with the study treatments or study assessments as deemed by the investigator, and refusal to remove beard or facial hair for duration of the study.
14. Subjects with non-stable dose of current (last 60 days) use of prescription rosacea medications.
15. Subjects with uncontrolled rosacea associated with inflammatory pustules and papules.
16. Study site staff, relatives of staff members, or other individuals who would have access to the clinical study protocol.
17. Subjects with participation in any investigational study within 30 days of entry into this study or concomitantly with this study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Mirvaso Gel	Brimonidine	Brimonidine topical gel, 0.33%

Primary Outcome Measures

Name	Time	Method
Pre-Treatment Clinician Erythema Assessment (CEA)	14 days (Day 1 (Baseline), Day 7, and Day 14/Exit)	The number and percent of subjects in each CEA score category at each visit. CEA was conducted at the screening/baseline visit and all subsequent visits prior to the study drug application.

Secondary Outcome Measures

Name	Time	Method
Inflammatory Lesions	14 days (Day 1 (Baseline) and Day 14/Exit)	Change from baseline in facial inflammatory lesion count
Facial Redness Visual Analog Scale (VAS)	14 days (Day 1 (Baseline), Day 14/Exit)	The number and percent of subjects in each transformed response category for the in-office subject reported facial redness VAS
Subject Facial Redness Questionnaire	14 days (Day 1 (Baseline) and Day 14/Exit)	Facial Redness Questionnaire at Day 1 and Day 14 (Mean Number of Subjects Who's Responses Indicate They Were/Were Not Bothered By Facial Redness, Across All 11 Facial Redness Questions)
Subject Treatment Satisfaction Questionnaire	14 days (Day 14/Exit)	Mean Subject Treatment Satisfaction at Day 14 (Average Response Across 12 Questions)

Trial Locations

Locations (12)

Redwood Dermatology Research; 🇺🇸 Santa Rosa, California, United States

Manhattan Dermatology and Cosmetic Surgery; 🇺🇸 New York, New York, United States

DermDox Centers for Dermatology; 🇺🇸 Hazleton, Pennsylvania, United States

Research Institute of the Southeast; 🇺🇸 West Palm Beach, Florida, United States

Blue Harbor Dermatology; 🇺🇸 Newport Beach, California, United States

Florida Academic Dermatology Center; 🇺🇸 Miami, Florida, United States

Arlington Research Center; 🇺🇸 Arlington, Texas, United States

Texas Dermatology and Laser Specialists; 🇺🇸 San Antonio, Texas, United States

Johnson Dermatology; 🇺🇸 Fort Smith, Arkansas, United States

Grekin Skin Institute; 🇺🇸 Warren, Michigan, United States

Advanced Skin Research Center; 🇺🇸 Omaha, Nebraska, United States

Center for Dermatology and Laser Surgery; 🇺🇸 Sacramento, California, United States